Granza Bio

About

Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunity.

Founders

• 
  Ashwin Nandakumar· Founder

  Ashwin completed his PhD (DPhil) in Oncology at the University of Oxford. After completing his PhD, he began working as a Cancer Research UK post-doctoral researcher at Oxford University and also at the Institute of Cancer Research (ICR), London. He also brings experience setting up oncology clinical trials and working in oncology start-ups.

  LinkedIn ↗Twitter ↗
• 
  Ashwin Jainarayanan· Founder

  Granza Bio, DPhil (PhD) in Interdisciplinary Bioscience - University of Oxford

  LinkedIn ↗

Product launches · 1 launch

• 🎯🦠 Granza Bio – Cancer targeting attack particles derived from our body’s immune system ↗▲ 762Feb 28, 2024

  We engineer "attack particles" that selectively target and kill cancer cells, eliminating unwanted side effects and toxicity.

Change history · none recorded